Gamida Cell actively pursuing strategic alternatives

Gamida Cell announced it is actively pursuing strategic alternatives in order to maximize value for all stakeholders, focusing on an asset sale, merger or other strategic transaction. However, there can be no assurance that the company’s strategic alternatives process will result in any such transaction. While pursuing strategic alternatives, the company continues to put its focus and resources behind the commercialization of Omisirge, the first and only FDA-approved nicotinamide modified cell therapy donor source for allogeneic stem cell transplant. Moelis & Company LLC is the company’s financial advisor for this process.